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bjectives The objective of this study was to evaluate the antiplatelet effect of clopidogrel 150
g/day in patients with high on-treatment reactivity (OTR) and to further assess this effect accord-
ng to CYP2C19 genotype.
ackground High OTR is associated with ischemic events in clopidogrel-treated patients after per-
utaneous coronary intervention. Alternative dosing regimens might enhance platelet inhibition.
ethods Patients with high OTR receiving a standard clopidogrel regimen were identiﬁed with the
erifyNow P2Y12 assay and administered clopidogrel 150 mg daily for 7 days, after which OTR was
eassessed. Comprehensive CYP2C19 genotyping was performed with the BeadXpress platform (Illu-
ina, San Diego, California) for the *2, *3, *4, *5, *6, *7, *8, and *17 variants.
esults A total of 41 subjects were enrolled, 20 of whom were carriers of a CYP2C19 loss-of-func-
ion (LoF) allele. High-dose clopidogrel signiﬁcantly reduced OTR from 285  47 P2Y12 reaction
nits (PRU) to 220  91 PRU (p  0.001). There were no signiﬁcant differences in antiplatelet effect
ccording to CYP2C19 status, although the reduction in reactivity was minimal in the small number
f patients homozygous for LoF alleles (n  3, 28  31 PRU, p  NS). Increasing body mass index
as independently and negatively associated with the reduction in OTR (p  0.009).
onclusions In patients with high OTR, clopidogrel 150 mg/day results in a signiﬁcant reduction in
latelet reactivity. Carriage of an LoF CYP2C19 polymorphism does not seem to have a major inﬂu-
nce on dose effect. The observed lack of effect in patients with 2 copies of a CYP2C19 LoF allele
ust be conﬁrmed by larger studies. (J Am Coll Cardiol Intv 2010;3:1001–7) © 2010 by the
merican College of Cardiology Foundation
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Increased Clopidogrel Dosing and Metabolizer Status
1002hen added to aspirin, clopidogrel reduces the incidence of
hrombotic vascular events among patients with acute cor-
nary syndromes and those undergoing percutaneous coro-
ary interventions (PCI) (1). However, many patients
aking dual antiplatelet therapy still experience thrombotic
vents. The pharmacodynamic effect of clopidogrel varies
idely among individuals (2). Patients with high on-
reatment reactivity (OTR) are at an increased risk for
ardiovascular events after PCI, including stent thrombosis
3–11). Therefore, investigation of the pharmacodynamic
ffect of alternative dosing regimens in these patients is
arranted.
See page 1008
Clopidogrel is a prodrug that undergoes hepatic biotrans-
ormation to its active metabolite by several enzymes of the
ytochrome P450 family, including CYP2C19 (12,13). Genetic
variants of CYP2C19, occurring as
either hetero- or homozygous al-
leles, impede the biotransforma-
tion of clopidogrel to its active
metabolite and seem to be impor-
tant determinants of a diminished
antiplatelet effect (14–18). The
CYP2C19 genotype might there-
fore influence the incremental re-
sponse to high-dose clopidogrel
therapy in patients with high
OTR to standard dosing.
In this study, we tested the
hypothesis that high-dose clo-
pidogrel maintenance therapy
would reduce platelet reactivity
in patients with high OTR. We
further examined the inter-
elationship between loss-of-function (LoF) variants of the
YP2C19 gene, platelet suppression, and high-dose therapy
n these patients.
ethods
ubjects and study design. This was an observational, lon-
itudinal, open-label, single-center study. Patients with
oronary artery disease (CAD) were eligible for enrollment
f they: 1) had received maintenance clopidogrel 75 mg/day
or 7 days or, if taking maintenance therapy for 7 days,
eceived a loading dose of clopidogrel 300 mg at the time
lopidogrel therapy was initiated; and 2) had high OTR,
efined as Verifynow P2Y12 reaction units (PRU) 235.
atients were excluded if they had been treated with a
lycoprotein IIb/IIIa inhibitor within 1 week; had active
leeding or history of recent bleeding diathesis (within 3
bbreviations
nd Acronyms
DP  adenosine
iphosphate
MI  body mass index
AD  coronary artery
isease
NA  deoxyribonucleic acid
oF  loss-of-function
TR  on-treatment
eactivity
CI  percutaneous
oronary intervention
PI  proton-pump inhibitor
RU  P2Y12 reaction unitsonths), a previous hemorrhagic stroke, intracranial neo- plasm, platelet count 100,000, hemoglobin 10 g/dl,
ntolerance to clopidogrel; or were being treated with oral
nticoagulation. This study complied with the Declaration
f Helsinki and was approved by the Scripps Clinic Insti-
utional Review Board. Informed consent was obtained
rom all patients.
tudy drug administration. Patients were administered clo-
idogrel 150 mg/day for 7 days, after which platelet reac-
ivity was reassessed. Compliance was assessed with pill
ounting.
latelet function measurements. The magnitude of on-
reatment platelet reactivity was measured with the Verify-
ow P2Y12 assay (Accumetrics, Inc., San Diego, Califor-
ia). The VerifyNow System is a turbidimetric-based
ptical detection system that measures platelet-induced
ggregation. The assay device contains a lyophilized prep-
ration of human-fibrinogen-coated beads, platelet activa-
ors, and buffer. The VerifyNow P2Y12 assay contains
0 mol adenosine diphosphate (ADP) and 22 nmol
rostaglandin E1 to reduce the activation contribution from
DP binding to P2Y12 receptors. The VerifyNow instru-
ent measures platelet-induced aggregation as an increase
n light transmittance and uses a proprietary algorithm to
eport values in PRU. With this assay, a higher PRU reflects
reater ADP-induced reactivity. Several prospective studies
ave demonstrated the ability of the VerifyNow P2Y12
ssay to identify patients at risk for cardiovascular events
fter PCI (6,19). “High OTR” was defined as a PRU235.
his cut-point has been demonstrated by receiver-operator
haracteristic curve analysis to predict 6-month ischemic
vents after PCI with drug-eluting stents and is similar to
utoffs that predict 30-day and 1-year major adverse cardiac
vents after PCI (3–6,20).
enetic methodology. DEOXYRIBONUCLEIC ACID (DNA) ISO-
ATION AND GENOTYPING. DNA was isolated from 200-l
liquots of frozen blood with the Qiagen QIAamp DNA
ini Kit (Qiagen, Valencia, California) and QiaCube
obotic workstation for automated DNA purification.
he CYP2C19 genotyping for the *2, *3, *4, *5, *6, *7, *8,
nd *17 single nucleotide polymorphisms was performed
ith the Illumina CYP2C19 Panel and Fast Goldengate
ssay on the BeadXpress Platform (Illumina, San Diego,
alifornia). Samples were run in duplicate along with 5
ositive control samples that have been previously char-
cterized for CYP2C19 genotypes with Sanger sequenc-
ng. The resulting genotypes had 100% reproducibility
47 of 47 matching calls across 42 patient samples and 5
ontrol samples), 100% concordance with Sanger se-
uencing results for the 5 positive control samples, and
00% sample call rates for all loci and samples. The *1
llele was assigned when none of the assayed alleles were
resent.
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1003LASSIFICATION BASED ON PREDICTED METABOLIC
HENOTYPE. Individual variants of the CYP2C19 gene were
lassified a priori according to their predicted metabolic
henotypes (ultra-rapid, extensive, intermediate, or poor
nzymatic function) according to published data (21) and
ith the use of the established common-consensus “star
llele” nomenclature (22). The *17/*17 or *1/*17 genotypes
ere classified as ultra-rapid metabolizers; *1/*1 were clas-
ified as extensive metabolizers; the combination of *1 with
LoF allele *2, *3, *4, *5, *6, *7, or *8 as intermediate
etabolizers; and any combination of 2 LoF alleles were
lassified as poor metabolizers. It was determined prospec-
ively to exclude genotypes with the combination of 1 *17
llele and an LoF allele from analyses, because the metabolic
henotypes of these combinations are unknown.
tatistical methods. The computer-based analysis program
PSS (Statistical Package for the Social Sciences, 12.0 for
C, SPSS, Inc., Chicago, Illinois) was used for statistical
alculations. Categorical variables are reported as counts
percentages), and continuous variables are reported as
ean SD. We tested differences between groups with the
hi-square test for categorical variables (or Fisher exact test
hen any expected cell count was 5 for a 2  2 table) and
ith an unpaired Student t test or 1-way analysis of variance
or continuous variables. The Kolmogorov-Smirnov test was
sed to test for a normal distribution. Linear and multiple
ogistic regression analyses (forward conditional) with vari-
bles with a p value of 0.20 on univariate analysis were
pplied to estimate the association between proposed vari-
bles and the change in OTR and the persistence of high
TR with high-dose maintenance therapy. A p value
0.05 was considered significant.
The primary end point of the study was the change in
TR with clopidogrel 150 mg/day. We estimated that,
ssuming an SD in OTR of 80 PRU (3,20), a total of 40
ubjects would provide a 90% power to see an effect size
Table 1. Baseline Clinical Characteristics of Study Population (n  41)
Age (yrs) 66.6 10.6
Male sex 35 (85.3%)
Diabetes mellitus 16 (39%)
Hypertension 36 (87.8%)
Hypercholesterolemia 36 (87.8%)
Previous cerebrovascular accident 4 (9.8%)
Previous myocardial infarction 13 (31.7%)
Previous coronary artery bypass surgery 15 (36.6%)
Previous PCI 33 (80.5%)
Concomitant proton-pump inhibitor use 10 (24.3%)
Body mass index (kg/m2) 29.3 5.6
Creatinine clearance (ml/min) 80.5 32.6
Index on-treatment reactivity (PRU) 285 47
PCI percutaneous coronary intervention; PRU P2Y12 reaction units.f 0.50 (i.e., a difference of 40 PRU) with a 1-sidedtudent t test. Assuming a CYP2C19 LoF allele carrier
ate of approximately 50% in patients with high OTR
15), this sample size would also provide a 70% power to
ee a 40-PRU difference in carriers compared with
oncarriers.
esults
aseline characteristics of the study population. A total of
1 subjects were enrolled. The baseline characteristics of
he study population are listed in Table 1. In brief, 35
atients (85%) were men, the average age was 66.6 
0.6 years, and 16 patients (39%) had diabetes mellitus.
he mean OTR on standard clopidogrel therapy was
85  47 PRU.
harmacodynamic effect of clopidogrel 150 mg/day. The
edian duration of therapy with clopidogrel 150 mg/day
as 8 days (range 7 to 12 days). The OTR was significantly
educed from 285  47 PRU to 220  91 PRU (p 
.001), with a mean decrement of 65 68 PRU and a mean
elative reduction of 24  24%.
YP2C19 status of the study population. Table 2 shows the
YP2C19 genotype distribution in the study population.
he allele frequencies of *1, *2, *3, *4, and *17 were 0.60,
.24, 0.024, 0.012, and 0.122, respectively. The variants *5,
6, *7, and *8 were not observed. A total of 20 subjects (49%)
ad at least 1 CYP2C19 LoF allele. With respect to
YP2C19 enzymatic function, 21 subjects (52.5%) were
ltra-rapid or extensive metabolizers (*17/*17, *1/*17, or
1/*1), 16 subjects (40%) were intermediate metabolizers
*1/*2, *1/*3, *1/*4), and 3 subjects (7.5%) were poor
etabolizers (*2/*2, *2/*3). One subject with *2/*17 geno-
ype was not included in the analysis, because the relation-
hip between this allelic combination and CYP2C19 enzy-
atic function is unknown.
YP2C19 status and pharmacodynamic effect of high
aintenance-dose clopidogrel. There was no difference in
aseline OTR between carriers of at least 1 CYP2C19 LoF
llele and noncarriers (292  40 PRU vs. 281  54 PRU,
 0.5). The reduction in OTR with clopidogrel 150
Table 2. Frequency of CYP2C19 Genotypes in Study Population
CYP2C19 Genotype Frequency
*1/*1 15 (36.6%)
*1/*2 14 (14.1%)
*1/*3 1 (2.4%)
*1/*4 1 (2.4%)
*1/*17 3 (7.3%)
*17/*17 3 (7.3%)
*2/*2 2 (4.8%)
*2/*3 1 (2.4%)
*2/*17 1 (2.4%)The genotypes *2/*4, *3/*3, *3/*4, and *4/*4 were not observed in the study population.
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1004g/day was not significantly different between carriers of at
east 1 LoF allele and noncarriers (52  66 PRU vs. 77 
2 PRU, p  0.25). The reduction in OTR was not
ignificantly different according to genotype, although pa-
ients homozygous for CYP2C19 LoF alleles had the least
eduction in reactivity (*17/*17 or *1/*17 genotypes: 61 75
RU; wild-type [*1/*1]: 84  72 PRU; heterozygotes [*1
ith an LoF allele *2, *3, *4, *5, *6, *7, or *8]: 56 71 PRU;
LoF alleles: 28  31 PRU, p  0.5) (Fig. 1).
linical characteristics and pharmacodynamic effect of high
aintenance-dose clopidogrel. The relationships between
he baseline clinical characteristics in Table 1 and the
hange in OTR were first tested by univariate analysis.
iabetic subjects tended to have a smaller reduction in
TR with high-dose maintenance clopidogrel compared
ith nondiabetic subjects (41  76 PRU vs. 81  60 PRU,
 0.067). There was a significant negative correlation
etween body mass index (BMI) and the reduction in OTR
r  0.41, p  0.009), and there was a negative trend
etween creatinine clearance and the reduction in OTR
r  0.29, p  0.068). The concomitant use of proton-
ump inhibitors (PPIs) had no effect on the response to
igh-dose maintenance therapy (reduction in OTR of 76 
3 PRU with PPIs vs. 63  68 PRU without PPIs, p 
.6). No other baseline characteristics were associated with
he change in OTR after clopidogrel 150 mg/day, including
Figure 1. CYP2C19 Status and Change in Platelet Reactivity
Reduction in on-treatment platelet reactivity with clopidogrel 150 mg/day
in subjects with high on-treatment reactivity to standard-dose clopidogrel,
stratiﬁed by carriage of no CYP2C19 loss-of-function (LoF) alleles or 1 or 2
CYP2C19 LoF alleles. P  0.4 between noncarriers and carriers (heterozy-
gous LoF and homozygous LoF).he level of OTR at the start of study drug treatment.Multivariate analysis was performed to determine the
haracteristics independently associated with the change
n OTR. Variables that, upon univariate analysis, had a
value 0.20 were entered into the model (diabetes,
reatinine clearance, and BMI). Only BMI was indepen-
ently associated with the change in OTR with high-
ose maintenance therapy (p  0.009).
ffect of clopidogrel 150 mg/day on high on-treatment
latelet reactivity. The OTR was “normalized” (PRU
235) by clopidogrel 150 mg/day in 23 subjects (56%).
able 3 shows the relationships among clinical characteris-
ics as well as CYP2C19 LoF allele carriage with persis-
ently high OTR. Subjects with persistently high OTR were
ore frequently diabetic (p  0.02), had a higher level of
TR with standard clopidogrel therapy before high-dose
dministration (p  0.001), and tended to have a greater
MI (p  0.09). The OTR on high-dose therapy was
ignificantly correlated with OTR on standard-dose therapy
r  0.68, p  0.001). On multivariate analysis with the
ariables in Table 3 with a p value of 0.20, a higher level
f OTR on standard clopidogrel was the only independent
redictor of persistently high OTR with clopidogrel 150
g/day (odds ratio: 1.029, 95% confidence interval: 1.01 to
.05, p  0.008). Diabetes mellitus tended to be associated
ith persistently high OTR on multivariate analysis, but
his relationship was not statistically significant (p  0.07).
iscussion
his is the first study to specifically examine the antiplatelet
ffect of increased maintenance-dose clopidogrel according
o CYP2C19 polymorphism status in a cohort of patients
ith high OTR with a diagnostic threshold that has been
Table 3. Relationship Between Persistently High OTR With Clopidogrel
150 mg/day and Baseline Characteristics
Characteristic
“Normalized” OTR
(n  23)
Persistently High OTR
(n  18) p Value
Age 66.4 9.6 66.8 12.0 0.90
Male sex 19 (82.6%) 16 (88.9%) 0.70
Diabetes mellitus 5 (21.7%) 11 (61.1%) 0.02
Hypertension 20 (87.0%) 18 (88.9%) 1.00
Hypercholesterolemia 21 (58.3%) 15 (41.7%) 0.60
Creatinine clearance (ml/min) 75.6 24.0 86.9 41.1 0.28
Previous CVA 4 (17.4%) 0 (0%) 0.12
Previous MI 7 (30.4%) 6 (33.3%) 1.00
Previous CABG 7 (30.4%) 8 (44.4%) 0.50
PPI use 6 (26.1%) 4 (22.2%) 1.00
Body mass index (kg/m2) 27.9 2.8 30.9 7.5 0.09
Index OTR (PRU) 265 28 312 54 0.001
CYP2C19 LoF allele carrier 10 (45.5%) 9 (50%) 1.00
CABG  coronary artery bypass graft surgery; CVA  cardiovascular accident; LoF  loss-of-
function;MImyocardial infarction; OTR on-treatment platelet reactivity; PPIproton-pumpinhibitor; PRU P2Y12 reaction units.
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1005hown to predict adverse clinical outcomes after PCI. Our
ajor findings are: 1) clopidogrel 150 mg/day significantly
educes platelet reactivity in the overall population of
atients with high OTR on standard therapy; 2) the
ncremental inhibition provided by 150 mg/day is largely
imilar regardless of CYP2C19 LoF polymorphism carrier
tatus, but the change in platelet reactivity was minimal and
eemed to be less in patients homozygous for CYP2C19 LoF
llele than that observed with wild-types or heterozygotes;
) BMI is independently and negatively associated with the
egree of incremental inhibition provided by the higher
ose; and 4) a heightened level of reactivity on standard
osing is a predictor of persistently high OTR, despite an
ncreased dose. These findings might have substantial clin-
cal implications for determining the appropriate type
nd/or dose of P2Y12 antagonist after PCI.
High OTR as determined by the VerifyNow P2Y12 assay
as been shown to be prognostic of cardiovascular risk after
CI by several prospective studies (3–6,20), but the optimal
harmacologic strategy to increase platelet inhibition in this
roup of patients is not known. In this pharmacodynamic
tudy, we observed that clopidogrel 150 mg/day significantly
educed platelet reactivity in patients with high OTR on
tandard therapy. Several studies have demonstrated that
igh-dose maintenance therapy reduces platelet reactivity
ompared with standard dose therapy in an unselected
ohort (23–25). In small studies that used various platelet
unction assays and definitions of suboptimal responsive-
ess, an increased maintenance seemed to provide further
nhibition (26–29) but not to the level of good responders
28,29). Our findings in a cohort of patients with CAD with
point-of-care platelet function assay and a well-defined
ptimal cut-point for high OTR are consistent with these
revious studies.
Because the CYP2C19 metabolic phenotype seems to
ictate the efficiency of clopidogrel active metabolite gen-
ration (17), we examined whether CYP2C19 LoF alleles
ight impact the antiplatelet effect of high-dose therapy in
atients with high OTR to standard therapy. This was a
omprehensive analysis and included CYP2C19 genotyping
or the *2, *3, *4, *5, *6, *7, *8, and *17 single nucleotide
olymorphisms. In a nonselected population, carriers of
YP2C19 *2 and *4 alleles have been shown to be responsive
o clopidogrel 150 mg/day (25), and the inhibitory re-
ponses to sequential 600-mg loading doses were similar in
YP2C19 *2 allele carriers and noncarriers (30). We did not
bserve, in our selected population of patients with high
TR, a statistically significant association between carriage
f at least 1 CYP2C19 LoF allele and the magnitude of
eduction in platelet reactivity with clopidogrel 150 mg/day.
owever, we did see a trend that patients with 2 CYP2C19
oF alleles had the least reduction in reactivity. Our
ndings are strengthened by the inclusion of a broad dpectrum of genetic variants that affect CYP2C19 metabo-
ism in addition to the *2 allele.
The U.S. Food and Drug Administration added a boxed
arning to the clopidogrel label in March 2010 that noted
hat tests are available to identify the CYP2C19 genotype of
patient. Furthermore, the warning states to “consider
lternative treatment or treatment strategies in patients
dentified as CYP2C19 poor metabolizers,” referring to an
npublished study of healthy volunteers that showed “im-
roved antiplatelet response” in 10 poor metabolizers
reated with clopidogrel 150 mg/day (31). We observed that
he antiplatelet effect of an increased clopidogrel dose
eemed minimal in a small number of CAD patients with
igh OTR who were CYP2C19 poor metabolizers. How-
ver, our findings are consistent with the U.S. Food and
rug Administration position on CYP2C19 genotyping,
ecause alternative P2Y12 inhibitors such as prasugrel and
icagrelor are not affected by CYP2C19 status (16,17,32),
nd therefore systematic CYP2C19 genotyping in patients
ndergoing platelet function testing could help select the
ppropriate P2Y12 inhibitor by identifying patients with
igh OTR who are poor metabolizers (i.e., patients with 2
opies of CYP2C19 *2, *3, *4, *5, *6, *7, and *8 alleles). The
mpact of our findings must be tempered by the small
ample size of our study. Given the low prevalence of poor
etabolizers in the population, only very large trials will be
ble to definitively assess the pharmacodynamic effect of
ncreased-dose clopidogrel in poor metabolizers with high
TR. The Genotype Information and Functional Testing
tudy (NCT00992420), a substudy of the GRAVITAS
Gauging Responsiveness with A VerifyNow Assay: Impact
n Thrombosis and Safety) trial (33), will help address this
uestion.
Drug under-dosage has been proposed as an etiology of
igh OTR in patients with greater BMI. High BMI is a
redictor of a poor response to a clopidogrel 300-mg
oading dose (34,35) and was a predictor of the inability of
epeated daily clopidogrel loading doses to achieve a
asodilator-stimulated phosphoprotein platelet reactivity in-
ex 50% in a small study using an unselected patient
ohort (30). We observed that greater BMI was indepen-
ently and negatively associated with the incremental re-
uction in OTR with increased maintenance-dose clopi-
ogrel in patients with high OTR on standard treatment.
herefore, our findings question whether even an increased
osage can achieve adequate levels of platelet inhibition in
bese patients with high OTR.
In clopidogrel-naïve patients, the level of post-treatment
eactivity is associated with pre-treatment reactivity (36).
e found that the change in reactivity with 150 mg/day was
ot dependent upon the level of reactivity on standard
herapy. However, a greater level of reactivity on standard
herapy independently predicted persistently high OTR,
espite the increased dose. For every 10-PRU increase in
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1006TR on standard therapy, the odds for persistently high
TR increased by 29%. Therefore, if the goal of intensified
ntiplatelet therapy is to “normalize” platelet reactivity to
elow the apparent diagnostic cutoff of the VerifyNow
2Y12 device, the use of alternative P2Y12 antagonists that
rovide consistent and powerful inhibition of the P2Y12
eceptor despite a poor clopidogrel response (37,38) might
e preferred in patients with very high OTR.
tudy limitations. This study has several limitations. First, it
as performed as a nonrandomized, observational, single-
enter study. Second, the study was not adequately powered
o detect differences in antiplatelet effect in poor metabo-
izers, and therefore our findings with regard to the minimal
ffect in this sub-group might be due to chance. However,
e were adequately powered to see an effect size in carriers
f at least 1 LoF allele (i.e., the combination of heterozy-
otes and homozygotes) that would likely be clinically
ignificant. Third, although data support the relationship
etween high OTR and cardiovascular risk after PCI, the
linical efficacy of antiplatelet therapy adjustment on the
asis of platelet function testing has not been established.
onclusions
n patients with high OTR despite standard clopidogrel
herapy, clopidogrel 150 mg/day provides a significant
eduction in the magnitude of platelet reactivity. Increasing
MI is an independent predictor of poor incremental
ntiplatelet effect with the higher dose, and patients with
igher levels of OTR to standard dosing are most likely to
ave persistently high OTR even with an increased dose. In
he few patients that were homozygous for a CYP2C19 LoF
llele, the antiplatelet effect with the higher dose of clopi-
ogrel seemed to be minimal. Therefore, higher-dose clo-
idogrel therapy improves antiplatelet response in patients
ith high OTR on standard therapy, but this effect might
e suboptimal in obese patients and those with very high
TR.
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